Hogan P A, Sheehan D J
U.S. Pharmaceuticals Group, Pfizer Inc., New York, New York 10017, USA.
Antimicrob Agents Chemother. 1998 Dec;42(12):3313-4. doi: 10.1128/AAC.42.12.3313.
In 1996 and 1997, 68 hospital laboratories throughout the United States determined the beta-lactamase production and susceptibility to macrolides of 1,998 isolates of Haemophilus influenzae obtained from patients with community-acquired respiratory tract infections. The MICs at which 90% of the isolates are inhibited of azithromycin, erythromycin, and clarithromycin were 4, 8, and 16 microgram/ml, respectively. By National Committee for Clinical Laboratory Standards interpretive criteria, 99 and 78% of the isolates were susceptible to azithromycin and clarithromycin, respectively. The prevalence of beta-lactamase production was 32%.
1996年和1997年,美国68家医院实验室对从社区获得性呼吸道感染患者中分离出的1998株流感嗜血杆菌进行了β-内酰胺酶产生情况及对大环内酯类药物敏感性的测定。阿奇霉素、红霉素和克拉霉素抑制90%分离株的最低抑菌浓度(MIC)分别为4、8和16微克/毫升。按照美国国家临床实验室标准委员会的解释标准,分别有99%和78%的分离株对阿奇霉素和克拉霉素敏感。β-内酰胺酶产生率为32%。